<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778189</url>
  </required_header>
  <id_info>
    <org_study_id>AssiutU_dexamethasone</org_study_id>
    <nct_id>NCT04778189</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Dexamethasone on Regression of Hyperbaric Bupivacaine Spinal Anesthesia in Lower Abdominal Surgery</brief_title>
  <official_title>Effect of Intravenous Dexamethasone on Regression of Hyperbaric Bupivacaine Spinal Anesthesia in Lower Abdominal Surgery , Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of dexamethasone, administered either systemically or perineurally, as an adjunct to&#xD;
      peripheral or neuraxial regional blocks, is currently one of the hottest topics in the field&#xD;
      of regional anesthesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large number of clinical studies have investigated this off-label application of&#xD;
      dexamethasone in recent years, with many reporting enhanced sensory block and/or improved&#xD;
      postoperative analgesia following either intravenous (i.v.) or perineural dexamethasone.&#xD;
      Dexamethasone is potent, selective glucocorticoid having minimal mineralocorticoid action.&#xD;
      Systemic anti-inflammatory and immunosuppressive properties may be responsible for the&#xD;
      prolongation of analgesia when administered intravenously. Various studies proved the&#xD;
      efficacy of steroids for the prolongation of the effects of regional nerve blocks. We decided&#xD;
      to conduct the present study to evaluate the effects of intravenous (IV) dexamethasone on the&#xD;
      subarachnoid block.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients will be scheduled for lower abdominal surgery under spinal anesthesia will randomly be allocated into two groups, group SD and group SN, After placement of standard monitors and peripheral IV access, with aseptic technique we will insert, a 25-G pencil-point Pencan(B. Braun, Mississauga, Ontario, Canada) needle intrathecally at the L4-5 or L3-4 interspace, with the patient in a seated position. We will confirm Intrathecal positioning by observation of cerebrospinal fluid return through the needle. Then we will inject the hyperbaric bupivacaine. All patients will receive spinal anesthesia with 12-mg hyperbaric bupivacaine 0.5%. Patients will be randomly assigned to one of the 2 Groups. Beginning during the intrathecal injection, patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline (total, 502 mL), while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes,</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in the motor block of spinal anesthesia</measure>
    <time_frame>5, 10, 20, and 30 minutes after injection of local anesthetic(LA)</time_frame>
    <description>change of motor block with the Bromage scale{I- Free movement of legs and feet, Nil (0%), II-Just able to flex knees with free movement of feet. Partial (33%), III-Unable to flex knees, but with free movement of feet.Almost complete (66%), IV-Unable to move legs or feet.Complete (100%)}</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change the sensory block of spinal anesthesia</measure>
    <time_frame>5, 10, 20, and 30 minutes after injection of LA</time_frame>
    <description>change of sensory block will be evaluated using a Von Frey6.1-g filament (Bioseb; North Coast Medical, Gilroy, CA)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Spinal Anesthesia</condition>
  <arm_group>
    <arm_group_label>normal saline group (NS)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes after spinal anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexamethasone group (SD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline in 5-10 minutes after spinal anesthesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>while patients in group( NS ) will receive 500-mL normal saline IV in 5-10 minutes, after spinal anesthesia</description>
    <arm_group_label>normal saline group (NS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>i.v dexmethasone</intervention_name>
    <description>patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia</description>
    <arm_group_label>dexamethasone group (SD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with American Society of Anesthesiologists score I-III,&#xD;
&#xD;
          -  Patients undergoing lower abdominal surgery under hyperbaric bupivacaine spinal&#xD;
             anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to amide LAs or dexamethasone,&#xD;
&#xD;
          -  Presence of a preexisting lower limb neurological deficit&#xD;
&#xD;
          -  Chronic use of corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amani H Abdel-wahab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amani H Abdel-wahab, MD</last_name>
    <phone>01004610623</phone>
    <email>amanyabdelwhab@aun.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>faculty of medicine Assiut university</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Amani H Abdei-wahab, MD</last_name>
      <phone>01004610623</phone>
      <email>amanyabdelwhab@aun.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amani Hassan Abdel-Wahab</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <keyword>i.v dexamethasone</keyword>
  <keyword>hyperparic bupivacaine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

